Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment
- PMID: 20179619
- DOI: 10.1097/IJG.0b013e3181d12dd8
Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment
Abstract
Purpose: To investigate whether the intraocular pressure (IOP) reduction and mechanism of action of timolol and latanoprost change between 1 and 6 weeks of treatment.
Patients and methods: Thirty participants on no ocular medications completed this double-masked, 6-visit, crossover study. At each visit IOP was determined by pneumatonometry, aqueous flow by fluorophotometry, and outflow facility by fluorophotometry and tonography. Separate values of uveoscleral outflow were calculated using the Goldmann equation, an episcleral venous pressure of 11 mm Hg, and each of the 2 outflow facility values. In a randomized fashion, both eyes were treated for 6 weeks with latanoprost 0.005% once daily or timolol 0.5% twice daily. Measurements were repeated at 1 and 6 weeks of dosing. After 6 weeks of washout, the second drug was administered in a crossover manner. One and 6 weeks of treatment were compared with appropriate baselines using 1-way analyses of variance (ANOVA).
Results: Timolol reduced aqueous flow by 27% at week 1 (P<0.001) and 16% at week 6 (P=0.03). Latanoprost increased uveoscleral outflow several fold at each visit (P<0.05). Neither drug altered outflow facility. Neither drug showed a detectable change in aqueous humor dynamics at week 6 compared with week 1. Both drugs significantly (P<0.001) reduced IOP at 1 and 6 weeks of treatment.
Conclusions: Timolol and latanoprost significantly reduce IOP by different mechanisms. Timolol reduces aqueous flow whereas latanoprost increases uveoscleral outflow. Continued treatment with timolol or latanoprost for 6 weeks did not alter effects on aqueous humor dynamics. Outflow facility changes sometimes reported with prostaglandin analogues were not detected in this study.
Similar articles
-
Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.J Glaucoma. 2007 Mar;16(2):189-95. doi: 10.1097/IJG.0b013e31802fc6d3. J Glaucoma. 2007. PMID: 17473728 Clinical Trial.
-
A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.Clin Ther. 2006 Mar;28(3):332-9. doi: 10.1016/j.clinthera.2006.03.001. Clin Ther. 2006. PMID: 16750448 Clinical Trial.
-
Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy.Arch Ophthalmol. 2012 Jun;130(6):677-84. doi: 10.1001/archophthalmol.2011.2573. Arch Ophthalmol. 2012. PMID: 22332206 Clinical Trial.
-
An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension.Expert Opin Pharmacother. 2004 Apr;5(4):909-21. doi: 10.1517/14656566.5.4.909. Expert Opin Pharmacother. 2004. PMID: 15102573 Review.
-
Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy.Surv Ophthalmol. 2002 Aug;47 Suppl 1:S155-61. doi: 10.1016/s0039-6257(02)00329-6. Surv Ophthalmol. 2002. PMID: 12204713 Review.
Cited by
-
A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.BMC Ophthalmol. 2012 May 18;12:9. doi: 10.1186/1471-2415-12-9. BMC Ophthalmol. 2012. PMID: 22607109 Free PMC article. Clinical Trial.
-
Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.J Ocul Pharmacol Ther. 2016 Dec;32(10):642-649. doi: 10.1089/jop.2016.0042. Epub 2016 Nov 11. J Ocul Pharmacol Ther. 2016. PMID: 27835065 Free PMC article.
-
Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use.J Ocul Pharmacol Ther. 2011 Feb;27(1):51-9. doi: 10.1089/jop.2010.0115. Epub 2010 Nov 30. J Ocul Pharmacol Ther. 2011. PMID: 21117945 Free PMC article.
-
Effect of Timolol on Aqueous Humor Outflow Facility in Healthy Human Eyes.Am J Ophthalmol. 2019 Jun;202:126-132. doi: 10.1016/j.ajo.2019.02.014. Epub 2019 Feb 19. Am J Ophthalmol. 2019. PMID: 30794789 Free PMC article.
-
The efficacy of a monocular drug trial in normal-tension glaucoma.Korean J Ophthalmol. 2012 Feb;26(1):26-31. doi: 10.3341/kjo.2012.26.1.26. Epub 2012 Jan 14. Korean J Ophthalmol. 2012. PMID: 22323882 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical